TheraRadar
← Back
Data updated: May 24, 2026

SUNSHINE

Generics
DermatologyInfectious DiseaseRespiratory Execution: Needs Improvement

SUNSHINE is a generic drug manufacturer focused on Dermatology, Infectious Disease, Respiratory.

2018
Since
25
Drugs
-
Trials
1
New Drugs (2yr)

SUNSHINE at a Glance

  • Growing R&D activity with 20 trials in last 2 years
  • Fast trial execution (17 months median completion)

Key Drugs

Top revenue-generating and strategically important drugs approved in the last 15 years. These represent the company's core commercial portfolio.

No active drugs

Recent FDA Approvals

New drug approvals (NDA/BLA) in the last 2 years. Shows novel drugs only, excluding generics and label supplements.

DULOXETINE HYDROCHLORIDE NDA
2026-02-27
duloxetine hydrochloride

Therapeutic Areas

Disease areas where this company has approved drugs and active pipeline. Weighted by commercial stage: approved drugs count most, followed by late-stage trials.

Dermatology 24%
3 drugs Phase 3: 6 Phase 2: 1 Phase 1: 4
Infectious Disease 24%
3 drugs Phase 3: 1 Phase 2: 5 Phase 1: 15
Respiratory 22%
3 drugs Phase 3: 3 Phase 2: 4 Phase 1: 6
Oncology 18%
0 drugs Phase 3: 3 Phase 2: 3 Phase 1: 18
Cardiovascular 12%
4 drugs

Pipeline Snapshot

Active clinical trials across all therapeutic areas. Data from ClinicalTrials.gov.

13
Phase 3
13
Phase 2
43
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Dermatology pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 4/11 completed
  • • Speed: 17 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges